Inflammatory biomarkers response to two dosages of vitamin D supplementation in patients with ulcerative colitis: A randomized, double-blind, placebo-controlled pilot study

Karimi, Sara; Tabataba-vakili, Sanam; Ebrahimi‐Daryani, Nasser; Yari, Zahra; Karimi, Abdolghader; Hedayati, Mehdi; Hekmatdoost, Azita

doi:10.1016/j.clnesp.2020.02.003

Cited by 10 publications

(1 citation statement)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A decrease in UCDAI was observed correlated with an increase in serum vitamin D, a reduction in C-reactive protein, and calprotectin. Patients with active UC who received vitamin D presented decreased DAI, serum C-reactive protein, and TNF level (271). However, another study demonstrated no difference of DAI or inflammatory markers on patients with UC supplemented with vitamin D (272).…”

Section: Vitamin Dmentioning

confidence: 94%

Inflammatory bowel disease therapeutic strategies by modulation of the microbiota: how and when to introduce pre-, pro-, syn-, or postbiotics?

Lê

Mantel

Marchix

et al. 2022

American Journal of Physiology-Gastrointestinal and Liver Physi

View full text Add to dashboard Cite

Inflammatory bowel diseases (IBD), a heterogeneous group of inflammatory conditions that encompass both ulcerative colitis and Crohn's disease, represent a major public health concern. The etiology of IBD is not yet fully understood and no cure is available, with current treatments only showing long-term effectiveness in a minority of patients. A need to increase our knowledge on IBD pathophysiology is growing, in order to define preventive measures, to improve disease outcome, and to develop new effective and lasting treatments. IBD pathogenesis is sustained by aberrant immune responses, associated with alterations of the intestinal epithelial barrier (IEB), modifications of the enteric nervous system and changes in microbiota composition. Currently, most of the treatments target the inflammation and the immune system, but holistic approaches targeting lifestyle and diet improvements are emerging. As dysbiosis is involved in IBD pathogenesis, pre-, pro-, syn- and postbiotics are used/tested to reduce the inflammation or strengthen the IEB. The present review will resume these works, pointing out the stage of life, the duration and the environmental conditions that should go along with microbiota or microbiota-derived treatments.

show abstract

Section: Vitamin Dmentioning

confidence: 94%